Structural analysis of mitochondrial cytochrome bc1 complex with atovaquone bound reveals the molecular basis of antimalarial drug action
Malaria Journal volume 13, Article number: P103 (2014)
The substituted hydroxynaphthoquinone atovaquone is a potent antimalarial drug in use for prevention and therapy, a fundamental part of the ongoing global medicinal strategy to control the disastrous infectious disease. Atovaquone acts via inhibition of the cytochrome bc1 complex (cyt bc1) and related mutations were linked to parasitic drug-resistance.
Materials and methods
We determined the 3.0-Å resolution X-ray structure of mitochondrial cyt bc1 from Saccharomyces cerevisiae with atovaquone bound in the catalytic Qo site . The drug, which has a pKa of 6.9, forms a polarized H-bond between its ionized hydroxyl group and His181 of the Rieske protein subunit. Multiple non-polar interactions with side chains of cytochrome b residues stabilize hydroxynaphthoquinone and chlorophenyl-cyclohexyl groups. The cytochrome b sequence analysis showed that the majority of the interacting residues are conserved, so that atovaquone binding to the yeast cyt bc1 is likely to resemble the binding to the complexes of the target organisms.
The binding mode provides detailed insights in the molecular basis of broad target spectrum, species-specific efficacies and acquired resistances. This may aid drug development to control the spread of drug-resistant parasites.
Birth D, Kao WC, Hunte C: Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat Commun. 2014, 5: 4029-
Kao WC, Hunte C: The molecular evolution of the Qo motif. Genome Biol Evol. 2014, 6: 1894-10.1093/gbe/evu147.
About this article
Cite this article
Birth, D., Kao, Wc. & Hunte, C. Structural analysis of mitochondrial cytochrome bc1 complex with atovaquone bound reveals the molecular basis of antimalarial drug action. Malar J 13 (Suppl 1), P103 (2014). https://doi.org/10.1186/1475-2875-13-S1-P103